{"organizations": [], "uuid": "b7489520b2d3324dffba06a76af4953f14bef0d2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-summit-therapeutics-says-muscle-da/brief-summit-therapeutics-says-muscle-damage-reduced-after-treatment-with-ezutromid-idUSASB0C2AY", "country": "US", "domain_rank": 408, "title": "BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-25T20:15:00.000+02:00", "replies_count": 0, "uuid": "b7489520b2d3324dffba06a76af4953f14bef0d2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-summit-therapeutics-says-muscle-da/brief-summit-therapeutics-says-muscle-damage-reduced-after-treatment-with-ezutromid-idUSASB0C2AY", "ord_in_thread": 0, "title": "BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid", "locations": [], "entities": {"persons": [], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Summit Therapeutics Plc:\n* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMITâ€™S PHASEOUT DMD CLINICAL TRIAL\n* SUMMIT THERAPEUTICS - TREATMENT WITH EZUTROMID RESULTED IN A STATISTICALLY SIGNIFICANT AND MEANINGFUL REDUCTION IN MUSCLE DAMAGE\n* SUMMIT THERAPEUTICS - IN PHASEOUT DMD TRIAL, 14 OF 22 PATIENTS SHOWED DECREASE IN DEVELOPMENTAL MYOSIN, WITH 5 SHOWING OVER 40% REDUCTION\n* SUMMIT THERAPEUTICS - TOP-LINE RESULTS OF PHASEOUT DMD TRIAL EXPECTED TO BE REPORTED IN Q3 2018\n* SUMMIT THERAPEUTICS - TO CONDUCT RANDOMISED, PLACEBO CONTROLLED TRIAL TO SUPPORT ACCELERATED, CONDITIONAL APPROVAL OF EZUTROMID IN US, EU RESPECTIVELY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T20:15:00.000+02:00", "crawled": "2018-01-26T21:37:45.016+02:00", "highlightTitle": ""}